Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01QQM
|
||||
| Former ID |
DNC004296
|
||||
| Drug Name |
LAMIFIBAN
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Angina pectoris [ICD9: 413; ICD10:I20] | Discontinued in Phase 3 | [545506] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C24H28N4O6
|
||||
| Canonical SMILES |
C1CN(CCC1OCC(=O)O)C(=O)C(CC2=CC=C(C=C2)O)NC(=O)C3=CC=C(<br />C=C3)C(=N)N
|
||||
| InChI |
1S/C24H28N4O6/c25-22(26)16-3-5-17(6-4-16)23(32)27-20(13-15-1-7-18(29)8-2-15)24(33)28-11-9-19(10-12-28)34-14-21(30)31/h1-8,19-20,29H,9-14H2,(H3,25,26)(H,27,32)(H,30,31)
|
||||
| InChIKey |
FPKOGTAFKSLZLD-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Glycoprotein IIb/IIIa receptor | Target Info | Modulator | ||
| Reactome | Platelet degranulation | ||||
| Elastic fibre formation | |||||
| PECAM1 interactions | |||||
| Molecules associated with elastic fibres | |||||
| Integrin cell surface interactions | |||||
| Syndecan interactions | |||||
| ECM proteoglycans | |||||
| Integrin alphaIIb beta3 signaling | |||||
| GRB2:SOS provides linkage to MAPK signaling for Integrins | |||||
| p130Cas linkage to MAPK signaling for integrins | |||||
| VEGFA-VEGFR2 Pathway | |||||
| MAP2K and MAPK activation | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.